Vitti Long Haul is an FDA registered, cGMP certified, and AATB accredited life sciences company pioneering pulmonary fibrosis clinical trials for patients with Long Haul COVID. Their proprietary combination therapy VL PX10, which uses umbilical cord MSC exosomes, and VL P22, containing umbilical cord MSCs with biomaterials, is in Phase 2 human trials to repair fibrotic lung tissue and reduce inflammation. An Expanded Access Program offers treatment to eligible patients outside the trial.